ERBB2 and neoplasm: Both investigated HER2 at the protein level with the HERmark® assay (Monogram Biosciences Inc., South San Francisco, CA, USA) and found that patients treated with trastuzumab with very high tumor HER2 expression were associated with worse prognosis [38, 45].